Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 4 June 2021, including: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas Pharma, Inc.’s mid-term ambitions; trial disappointment for Novartis AG’s Beovu; and Indian plans for a pediatric COVID vaccine.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode: